Community associated methicillin resistant staphylococcal infections in a pediatric urology practice

The Journal of Urology
Michelle E KoskiJohn C Thomas

Abstract

Methicillin resistant Staphylococcus aureus is a virulent organism that has seen a rapid increase in prevalence. Community associated methicillin resistant S. aureus is discussed frequently in the infectious disease community. However, there has been little mention of this entity in the urological literature. We reviewed the records of patients presenting with skin/soft tissue infections or documented methicillin resistant S. aureus infection treated at an academic pediatric urology practice between October 2004 and August 2006. A total of 12 patients were included (33% female, 67% male). Mean patient age was 49 months (range 8 to 202). Of the patients 11 (92%) presented with spontaneous infection and 1 (8%) presented with a wound infection. Abscess location was inguinal in 4 patients (33%), scrotal in 3 (25%), perineal in 2 (17%), perinephric in 2 (17%) and labial in 1 (8%). The most common presenting sign at referral was fluctuance (30%). While all patients eventually required surgical drainage, initial treatment by the primary care physician consisted of observation on oral antibiotics in 7 patients (58%). A total of 10 cultures (83%) revealed methicillin resistant S. aureus and 2 cultures (17%) were negative. Mean hospital ...Continue Reading

References

Dec 1, 1985·Antimicrobial Agents and Chemotherapy·M T CafferkeyC T Keane
Mar 4, 1999·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·S TorvaldsenT V Riley
Sep 5, 2001·The Journal of Antimicrobial Chemotherapy·R A VeneziaE M Graffunder
Aug 17, 2002·The Pediatric Infectious Disease Journal·Arthur L FrankJohn P Quinn
Nov 7, 2002·MMWR. Morbidity and Mortality Weekly Report·UNKNOWN Centers for Disease Control and Prevention (CDC)
Nov 14, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Lona ModySuzanne F Bradley
Dec 11, 2003·JAMA : the Journal of the American Medical Association·Timothy S NaimiRuth Lynfield
Dec 18, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Daniel J DiekemaBradley N Doebbeling
Feb 16, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Stan Deresinski
Apr 9, 2005·The New England Journal of Medicine·Scott K FridkinUNKNOWN Active Bacterial Core Surveillance Program of the Emerging Infections Program Network
Apr 22, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jorg J RuheAnupama Menon
Nov 1, 2005·Current Opinion in Infectious Diseases·Michael W Ellis, James S Lewis
Mar 2, 2006·The Journal of Antimicrobial Chemotherapy·Curtis G GemmellUNKNOWN Joint Working Party of the British Society for Joint Working Party of the British Society for Antimicrobial Chemotherapy, Ho

❮ Previous
Next ❯

Citations

Oct 29, 2011·BMC Pediatrics·Alexis C McCulloughDeepa Mukundan
Mar 5, 2013·The Journal of Urology·Naveen DivakaruniCourtney M P Hollowell
Feb 20, 2009·Current Opinion in Otolaryngology & Head and Neck Surgery

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Related Papers

JAMA : the Journal of the American Medical Association
Timothy S NaimiRuth Lynfield
JAMA : the Journal of the American Medical Association
R Monina KlevensActive Bacterial Core surveillance (ABCs) MRSA Investigators
Antimicrobial Agents and Chemotherapy
Bruno Périchon, Patrice Courvalin
Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America
David K WarrenMarin H Kollef
© 2021 Meta ULC. All rights reserved